BackAprea Therapeutics Overview

Aprea Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$1.61M
35.11% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$6.17M
39.77% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Aprea Therapeutics (APRE) FAQ

Stockcircle tracks research & development for Aprea Therapeutics (APRE), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Aprea Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main APRE overview so you can move from this figure to the surrounding analysis quickly.